Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia

This publication has 70 references indexed in Scilit:

• Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
  Nature Reviews Drug Discovery, 2009
• Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia
  Trends in Neurosciences, 2008
• Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated
  Neuropharmacology, 2008
• Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
  Nature Medicine, 2007
• Dysfunctional and Compensatory Prefrontal Cortical Systems, Genes and the Pathogenesis of Schizophrenia
  Cerebral Cortex, 2007
• Positive Allosteric Modulation of Metabotropic Glutamate 5 (mGlu5) Receptors Reverses N-Methyl-D-Aspartate Antagonist-Induced Alteration of Neuronal Firing in Prefrontal Cortex
  Biological Psychiatry, 2007
• NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin
  Neuropharmacology, 2005
• Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): Efficacy in an animal model for schizophrenia
  Bioorganic & Medicinal Chemistry Letters, 2005
• A novel, competitive mGlu₅ receptor antagonist (LY344545) blocks DHPG‐induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices
  British Journal of Pharmacology, 2000
• Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications
  Life Sciences, 1997